Recently, we conducted a retrospective analysis on a cohort of 112 TNBC and HR-/HER2+ breast cancer patients receiving neoadjuvant treatment, which was in the majority of the cases a combination of epirubicin and cyclophosphamide followed by taxanes (plus trastuzumab for HER2+ patients) [72]. Here, ERBB2 is linked to breast cancer.